Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotatercept added to background therapy in high-risk pulmonary arterial hypertension
NL-OMON54241Phase 3Recruiting
- Sponsor
- Acceleron Pharma Inc.
- Start
- Aug 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Placebo plus background PAH therapy with Sotatercept plus background PAH therapy (2 arms). Primary endpoint: Time to first composite morbidity or mortality event. Started Aug 2022; status: recruiting.
02
Drugs
sotatercept
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NL-OMON54241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54241.